Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shihchen Kuo

Showing results (11-20 of 70) with videos related to

Pageof 7
Sort By:
Diabetes Research and Clinical Practice|March 16, 2023
Value of GLP-1 receptor agonists versus long-acting insulins for type 2 diabetes patients with and without established cardiovascular or chronic kidney diseases: A model-based cost-effectiveness analysis using real-world dataChun-Ting Yang, Wen-Yu Yao, Huang-Tz Ou, et al.
Cardiovascular Diabetology|June 15, 2020
Comparative cardiovascular safety of GLP-1 receptor agonists versus other glucose-lowering agents in real-world patients with type 2 diabetes: a nationwide population-based cohort studyChun-Ting Yang, Chen-Yi Yang, Huang-Tz Ou, et al.
Cardiovascular Diabetology|November 25, 2025
Temporal and subgroup disparities in mediation effects on cardiovascular outcomes with liraglutide and semaglutide: a post-hoc analysis of LEADER and SUSTAIN-6 trialsZi-Yang Peng, Yu-Hsuan Lee, Huang-Tz Ou, et al.
Diabetes, Obesity & Metabolism|September 7, 2018
Effects on clinical outcomes of intensifying triple oral antidiabetic drug (OAD) therapy by initiating insulin versus enhancing OAD therapy in patients with type 2 diabetes: A nationwide population-based, propensity-score-matched cohort studyShihchen Kuo, Chun-Ting Yang, Jin-Shang Wu, et al.
Cardiovascular Diabetology|January 20, 2021
Cost-effectiveness of GLP-1 receptor agonists versus insulin for the treatment of type 2 diabetes: a real-world study and systematic reviewChen-Yi Yang, Ying-Ren Chen, Huang-Tz Ou, et al.
Cardiovascular Research|November 5, 2024
Temporal changes in mediation effects on cardiovascular and microvascular outcomes with glucagon-like peptide-1 receptor agonist therapy: a post-hoc analysis of the LEADER trialZi-Yang Peng, Yu-Hsuan Lee, Huang-Tz Ou, et al.
Diabetes Care|July 14, 2022
National Trends in the Achievement of Recommended Strategies for Stroke Prevention in U.S. Adults With Type 2 Diabetes, 2001-2018Shihchen Kuo, Chun-Ting Yang, William H Herman, et al.
Scientific Reports|January 8, 2022
Three-step matching algorithm to enhance between-group comparability and minimize confounding in comparative effectiveness studiesChen-Yi Yang, Shihchen Kuo, Edward Chia-Cheng Lai, et al.
Cardiovascular Diabetology|July 8, 2020
Comparative predictive ability of visit-to-visit HbA1c variability measures for microvascular disease risk in type 2 diabetesChen-Yi Yang, Pei-Fang Su, Jo-Ying Hung, et al.
Scientific Reports|February 19, 2021
A nationwide cohort study for comparative vascular safety of long-acting insulin analogue versus intermediate-acting human insulin in type 2 diabetesChun-Ting Yang, Kuan-Ying Li, Chen-Yi Yang, et al.
Pageof 7

Showing results (11-20 of 70) with videos related to

Sort By:
Pageof 7
Diabetes Research and Clinical Practice|March 16, 2023
Value of GLP-1 receptor agonists versus long-acting insulins for type 2 diabetes patients with and without established cardiovascular or chronic kidney diseases: A model-based cost-effectiveness analysis using real-world dataChun-Ting Yang, Wen-Yu Yao, Huang-Tz Ou, et al.
Cardiovascular Diabetology|June 15, 2020
Comparative cardiovascular safety of GLP-1 receptor agonists versus other glucose-lowering agents in real-world patients with type 2 diabetes: a nationwide population-based cohort studyChun-Ting Yang, Chen-Yi Yang, Huang-Tz Ou, et al.
Cardiovascular Diabetology|November 25, 2025
Temporal and subgroup disparities in mediation effects on cardiovascular outcomes with liraglutide and semaglutide: a post-hoc analysis of LEADER and SUSTAIN-6 trialsZi-Yang Peng, Yu-Hsuan Lee, Huang-Tz Ou, et al.
Diabetes, Obesity & Metabolism|September 7, 2018
Effects on clinical outcomes of intensifying triple oral antidiabetic drug (OAD) therapy by initiating insulin versus enhancing OAD therapy in patients with type 2 diabetes: A nationwide population-based, propensity-score-matched cohort studyShihchen Kuo, Chun-Ting Yang, Jin-Shang Wu, et al.
Cardiovascular Diabetology|January 20, 2021
Cost-effectiveness of GLP-1 receptor agonists versus insulin for the treatment of type 2 diabetes: a real-world study and systematic reviewChen-Yi Yang, Ying-Ren Chen, Huang-Tz Ou, et al.
Cardiovascular Research|November 5, 2024
Temporal changes in mediation effects on cardiovascular and microvascular outcomes with glucagon-like peptide-1 receptor agonist therapy: a post-hoc analysis of the LEADER trialZi-Yang Peng, Yu-Hsuan Lee, Huang-Tz Ou, et al.
Diabetes Care|July 14, 2022
National Trends in the Achievement of Recommended Strategies for Stroke Prevention in U.S. Adults With Type 2 Diabetes, 2001-2018Shihchen Kuo, Chun-Ting Yang, William H Herman, et al.
Scientific Reports|January 8, 2022
Three-step matching algorithm to enhance between-group comparability and minimize confounding in comparative effectiveness studiesChen-Yi Yang, Shihchen Kuo, Edward Chia-Cheng Lai, et al.
Cardiovascular Diabetology|July 8, 2020
Comparative predictive ability of visit-to-visit HbA1c variability measures for microvascular disease risk in type 2 diabetesChen-Yi Yang, Pei-Fang Su, Jo-Ying Hung, et al.
Scientific Reports|February 19, 2021
A nationwide cohort study for comparative vascular safety of long-acting insulin analogue versus intermediate-acting human insulin in type 2 diabetesChun-Ting Yang, Kuan-Ying Li, Chen-Yi Yang, et al.
Pageof 7